---
title: "Bleichroeder Acquisition I - Unit | 10-Q: FY2025 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265598603.md"
datetime: "2025-11-12T22:29:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265598603.md)
  - [en](https://longbridge.com/en/news/265598603.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265598603.md)
generator: "portal-rs"
---

# Bleichroeder Acquisition I - Unit | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD 0.

EBIT: As of FY2025 Q3, the actual value is USD -5.315 M.

### Segment Revenue

-   The company has not generated any operating revenues as of September 30, 2025, and will not do so until after the completion of its initial Business Combination.

### Operational Metrics

-   **Net Income (Loss):** For the three months ended September 30, 2025, the company reported a net income of $83,694, compared to a net loss of $47,447 for the same period in 2024. For the nine months ended September 30, 2025, the net income was $4,809,256, compared to a net loss of $77,427 for the period from June 24, 2024 (inception) through September 30, 2024.
-   **General and Administrative Expenses:** These expenses were $2,615,816 for the three months ended September 30, 2025, and $3,212,856 for the nine months ended September 30, 2025.

### Cash Flow

-   **Operating Cash Flow:** For the nine months ended September 30, 2025, net cash used in operating activities was - $1,057,906.
-   **Investments Held in Trust Account:** As of September 30, 2025, the investments held in the Trust Account amounted to $259,730,180.

### Unique Metrics

-   **Interest Income:** Interest earned on investments held in the Trust Account was $2,685,470 for the three months ended September 30, 2025, and $7,973,982 for the nine months ended September 30, 2025.

### Future Outlook and Strategy

-   **Core Business Focus:** The company intends to complete the Merlin Labs Business Combination, which involves merging with Merlin Labs, Inc., with the combined company continuing to operate through Merlin Labs and its subsidiaries. The company will change its name to Merlin Labs, Inc. upon closing.
-   **Non-Core Business:** The company has entered into a Sponsor Support Agreement and a Stockholder Voting and Support Agreement to facilitate the completion of the Business Combination with Merlin Labs. These agreements include commitments to vote in favor of the Business Combination and to convert certain shares as part of the transaction.
-   **Priority:** The company plans to complete the initial Business Combination before the end of the Combination Period, which is currently set for November 6, 2026.

### Related Stocks

- [BACQU.US](https://longbridge.com/en/quote/BACQU.US.md)

## Related News & Research

- [Is Quanta Services (PWR) Trading At A Premium To Fair Value?](https://longbridge.com/en/news/298820833.md)
- [German firms lift China investment as US outlays fall, IW study shows](https://longbridge.com/en/news/298822930.md)
- [Baxter International (BAX) Could Be 17% Undervalued Following Its Hospital Recovery Narrative](https://longbridge.com/en/news/298839307.md)
- [How Higher Earnings Estimates Will Impact ITT Stock Investors](https://longbridge.com/en/news/298839258.md)
- [e.l.f. Beauty (ELF) Expands Naturium At Sephora, Is The Upside Already Priced In?](https://longbridge.com/en/news/298839317.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**